Tudor Investment Corp ET AL acquired a new position in shares of AtriCure, Inc. (NASDAQ:ATRC) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 10,435 shares of the medical device company’s stock, valued at approximately $253,000.
Other institutional investors also recently made changes to their positions in the company. Wells Fargo & Company MN grew its position in shares of AtriCure by 131.9% during the first quarter. Wells Fargo & Company MN now owns 112,006 shares of the medical device company’s stock worth $2,145,000 after buying an additional 63,711 shares in the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in AtriCure during the first quarter worth approximately $329,000. Royce & Associates LP lifted its stake in AtriCure by 12.7% during the second quarter. Royce & Associates LP now owns 302,400 shares of the medical device company’s stock worth $7,333,000 after purchasing an additional 34,100 shares during the last quarter. Neuberger Berman Group LLC lifted its stake in AtriCure by 45.5% during the second quarter. Neuberger Berman Group LLC now owns 824,469 shares of the medical device company’s stock worth $19,993,000 after purchasing an additional 257,949 shares during the last quarter. Finally, Swiss National Bank lifted its stake in AtriCure by 7.0% during the first quarter. Swiss National Bank now owns 54,700 shares of the medical device company’s stock worth $1,048,000 after purchasing an additional 3,600 shares during the last quarter. 82.11% of the stock is owned by institutional investors and hedge funds.
Several equities research analysts recently weighed in on ATRC shares. Zacks Investment Research upgraded AtriCure from a “sell” rating to a “hold” rating in a research note on Monday, October 2nd. BidaskClub cut AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Canaccord Genuity restated a “buy” rating and set a $28.00 target price on shares of AtriCure in a research note on Monday, October 9th. Stifel Nicolaus restated a “buy” rating and set a $25.00 target price on shares of AtriCure in a research note on Sunday, July 30th. Finally, Needham & Company LLC restated a “buy” rating and set a $26.00 target price (up previously from $25.00) on shares of AtriCure in a research note on Friday, July 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $25.83.
In related news, Director Elizabeth D. Krell sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $22.40, for a total transaction of $224,000.00. Following the transaction, the director now directly owns 29,967 shares in the company, valued at $671,260.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.00% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://stocknewstimes.com/2017/10/17/tudor-investment-corp-et-al-takes-253000-position-in-atricure-inc-atrc.html.
Shares of AtriCure, Inc. (NASDAQ:ATRC) opened at 22.61 on Tuesday. The firm’s market cap is $776.29 million. The firm’s 50-day moving average price is $21.85 and its 200-day moving average price is $21.95. AtriCure, Inc. has a 52 week low of $14.78 and a 52 week high of $25.18.
AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, July 27th. The medical device company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.05. AtriCure had a negative return on equity of 19.56% and a negative net margin of 19.56%. The business had revenue of $45.23 million during the quarter, compared to analysts’ expectations of $44.15 million. During the same quarter in the previous year, the firm earned ($0.26) EPS. The firm’s revenue was up 14.0% compared to the same quarter last year. Equities research analysts expect that AtriCure, Inc. will post ($0.95) EPS for the current fiscal year.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC).
Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.